NASDAQ:TNDM

Tandem Diabetes Care Stock Forecast, Price & News

$93.76
+0.04 (+0.04 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$93.30
$95.19
50-Day Range
$77.00
$95.96
52-Week Range
$76.19
$123.74
Volume534,037 shs
Average Volume719,816 shs
Market Capitalization$5.87 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.21
30 days | 90 days | 365 days | Advanced Chart
Receive TNDM News and Ratings via Email

Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter.


Tandem Diabetes Care logo

About Tandem Diabetes Care

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. Its products in development include t:sport insulin delivery system; and connected (mobile) health offerings. Tandem Diabetes Care, Inc. has a development and commercialization agreement with Dexcom, Inc. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.87 out of 5 stars

Medical Sector

151st out of 2,097 stocks

Surgical & Medical Instruments Industry

17th out of 174 stocks

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Tandem Diabetes Care (NASDAQ:TNDM) Frequently Asked Questions

Is Tandem Diabetes Care a buy right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Tandem Diabetes Care stock.
View analyst ratings for Tandem Diabetes Care
or view top-rated stocks.

What stocks does MarketBeat like better than Tandem Diabetes Care?

Wall Street analysts have given Tandem Diabetes Care a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tandem Diabetes Care wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Tandem Diabetes Care's next earnings date?

Tandem Diabetes Care is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Tandem Diabetes Care
.

How were Tandem Diabetes Care's earnings last quarter?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) issued its quarterly earnings results on Wednesday, May, 5th. The medical device company reported ($0.08) EPS for the quarter, topping the Zacks' consensus estimate of ($0.16) by $0.08. The medical device company earned $141.04 million during the quarter, compared to analysts' expectations of $122.66 million. Tandem Diabetes Care had a negative net margin of 4.53% and a negative trailing twelve-month return on equity of 1.12%.
View Tandem Diabetes Care's earnings history
.

How has Tandem Diabetes Care's stock price been impacted by Coronavirus (COVID-19)?

Tandem Diabetes Care's stock was trading at $66.33 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TNDM shares have increased by 41.4% and is now trading at $93.76.
View which stocks have been most impacted by COVID-19
.

When did Tandem Diabetes Care's stock split? How did Tandem Diabetes Care's stock split work?

Tandem Diabetes Care shares reverse split before market open on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.

What guidance has Tandem Diabetes Care issued on next quarter's earnings?

Tandem Diabetes Care updated its FY 2021 earnings guidance on Wednesday, May, 26th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $625 million-$640 million, compared to the consensus revenue estimate of $610.52 million.

What price target have analysts set for TNDM?

13 analysts have issued 1-year price targets for Tandem Diabetes Care's stock. Their forecasts range from $90.00 to $150.00. On average, they anticipate Tandem Diabetes Care's share price to reach $118.77 in the next year. This suggests a possible upside of 26.7% from the stock's current price.
View analysts' price targets for Tandem Diabetes Care
or view top-rated stocks among Wall Street analysts.

Who are Tandem Diabetes Care's key executives?

Tandem Diabetes Care's management team includes the following people:
  • Mr. John F. Sheridan, Pres, CEO & Director (Age 66, Pay $1.09M)
  • Ms. Leigh A. Vosseller, Exec. VP, CFO & Treasurer (Age 48, Pay $618.17k)
  • Ms. Susan M. Morrison, Exec. VP & Chief Admin. Officer (Age 42, Pay $616.87k)
  • Mr. David B. Berger, Exec. VP, Chief Bus. Operations & Compliance Officer and Corp. Sec. (Age 51, Pay $617.65k)
  • Mr. Brian B. Hansen, Exec. VP & Chief Commercial Officer (Age 53, Pay $618.65k)
  • Mr. Jim Leal, Sr. VP of Operations
  • Mr. Manuel Jaime, Sr. VP of Technology & Digital Health
  • Mr. Ross Sylvia, VP of Marketing
  • Ms. Elizabeth A. Gasser, Exec. VP of Strategy & Corp. Devel. (Age 45)
  • Mr. Tom Fox, Sr. VP of HR & Organizational Devel.

What is John Sheridan's approval rating as Tandem Diabetes Care's CEO?

11 employees have rated Tandem Diabetes Care CEO John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among Tandem Diabetes Care's employees.

Who are some of Tandem Diabetes Care's key competitors?

What other stocks do shareholders of Tandem Diabetes Care own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Square (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL).

What is Tandem Diabetes Care's stock symbol?

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Who are Tandem Diabetes Care's major shareholders?

Tandem Diabetes Care's stock is owned by a number of institutional and retail investors. Top institutional investors include Jackson Square Partners LLC (5.92%), BlackRock Inc. (5.58%), Credit Suisse AG (3.24%), Champlain Investment Partners LLC (2.14%), Brown Capital Management LLC (1.96%) and RTW Investments LP (1.82%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Rebecca B Robertson and Susan Morrison.
View institutional ownership trends for Tandem Diabetes Care
.

Which major investors are selling Tandem Diabetes Care stock?

TNDM stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, Gilder Gagnon Howe & Co. LLC, Sectoral Asset Management Inc, Price T Rowe Associates Inc. MD, Renaissance Technologies LLC, UBS Asset Management Americas Inc., Ameriprise Financial Inc., and Morgan Stanley. Company insiders that have sold Tandem Diabetes Care company stock in the last year include Brian B Hansen, Christopher J Twomey, David B Berger, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Rebecca B Robertson, and Susan Morrison.
View insider buying and selling activity for Tandem Diabetes Care
or view top insider-selling stocks.

Which major investors are buying Tandem Diabetes Care stock?

TNDM stock was bought by a variety of institutional investors in the last quarter, including Champlain Investment Partners LLC, Credit Suisse AG, Jackson Square Partners LLC, RTW Investments LP, Point72 Asset Management L.P., First Light Asset Management LLC, Compagnie Lombard Odier SCmA, and Assenagon Asset Management S.A..
View insider buying and selling activity for Tandem Diabetes Care
or or view top insider-buying stocks.

How do I buy shares of Tandem Diabetes Care?

Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tandem Diabetes Care's stock price today?

One share of TNDM stock can currently be purchased for approximately $93.76.

How much money does Tandem Diabetes Care make?

Tandem Diabetes Care has a market capitalization of $5.87 billion and generates $498.83 million in revenue each year. The medical device company earns $-34,380,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis.

How many employees does Tandem Diabetes Care have?

Tandem Diabetes Care employs 1,500 workers across the globe.

What is Tandem Diabetes Care's official website?

The official website for Tandem Diabetes Care is www.tandemdiabetes.com.

Where are Tandem Diabetes Care's headquarters?

Tandem Diabetes Care is headquartered at 11075 ROSELLE STREET, San Diego CA, 92121.

How can I contact Tandem Diabetes Care?

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at 858-366-6900 or via email at [email protected]


This page was last updated on 6/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.